このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Teyi Pharmaceutical GroupLtd 将来の成長

Future 基準チェック /36

Teyi Pharmaceutical GroupLtd は収益が増加すると予測されています。EPS は、年間増加すると予測されています42.5%。

主要情報

41.1%

収益成長率

42.5%

EPS成長率

Pharmaceuticals 収益成長	18.8%
収益成長率	n/a
将来の株主資本利益率	17.1%
アナリストカバレッジ	Low
最終更新日	20 May 2024

今後の成長に関する最新情報

更新なし

Recent updates

We Think Teyi Pharmaceutical GroupLtd (SZSE:002728) Can Stay On Top Of Its Debt

Jun 06

Why Teyi Pharmaceutical GroupLtd's (SZSE:002728) Shaky Earnings Are Just The Beginning Of Its Problems

Apr 26

Teyi Pharmaceutical Group Co.,Ltd's (SZSE:002728) Shares Bounce 29% But Its Business Still Trails The Market

Mar 06

Here's Why We Think Teyi Pharmaceutical GroupLtd (SZSE:002728) Is Well Worth Watching

Feb 27

業績と収益の成長予測

SZSE:002728 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2024	843	104	-5	98	N/A
3/31/2024	928	157	42	132	N/A
12/31/2023	1,067	253	113	199	N/A
9/30/2023	1,049	269	223	317	N/A
6/30/2023	1,040	269	267	363	N/A
3/31/2023	996	238	282	372	N/A
12/31/2022	887	178	281	372	N/A
9/30/2022	816	122	136	216	N/A
6/30/2022	785	113	107	206	N/A
3/31/2022	758	131	98	207	N/A
1/1/2022	758	127	147	257	N/A
9/30/2021	725	118	146	258	N/A
6/30/2021	691	92	130	231	N/A
3/31/2021	652	63	116	213	N/A
12/31/2020	633	44	80	169	N/A
9/30/2020	668	66	35	143	N/A
6/30/2020	743	108	63	176	N/A
3/31/2020	852	155	105	221	N/A
12/31/2019	921	172	91	222	N/A
9/30/2019	939	168	51	213	N/A
6/30/2019	949	171	48	217	N/A
3/31/2019	926	171	44	209	N/A
12/31/2018	885	156	36	188	N/A
9/30/2018	828	146	69	166	N/A
6/30/2018	777	128	62	132	N/A
3/31/2018	739	112	N/A	102	N/A
12/31/2017	687	106	N/A	103	N/A
9/30/2017	689	110	N/A	72	N/A
6/30/2017	680	105	N/A	103	N/A
3/31/2017	650	94	N/A	154	N/A
12/31/2016	656	95	N/A	101	N/A
9/30/2016	648	85	N/A	145	N/A
6/30/2016	631	84	N/A	67	N/A
3/31/2016	584	80	N/A	7	N/A
12/31/2015	517	81	N/A	69	N/A
9/30/2015	419	78	N/A	23	N/A
6/30/2015	356	74	N/A	68	N/A
3/31/2015	355	78	N/A	59	N/A
12/31/2014	345	80	N/A	57	N/A
9/30/2014	347	82	N/A	97	N/A
6/30/2014	345	85	N/A	N/A	N/A
3/31/2014	337	82	N/A	N/A	N/A
12/31/2013	343	81	N/A	74	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 002728の予測収益成長率 (年間41.1% ) は貯蓄率 ( 2.9% ) を上回っています。

収益対市場: 002728の収益 ( 41.1% ) はCN市場 ( 21.9% ) よりも速いペースで成長すると予測されています。

高成長収益: 002728の収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: 002728の収益がCN市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: 002728の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 002728の自己資本利益率は、3年後には低くなると予測されています ( 17.1 %)。

Teyi Pharmaceutical GroupLtd 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Recent updates

Now 24% overvalued

Now 20% overvalued

Teyi Pharmaceutical Group Co.,Ltd to Report First Half, 2024 Results on Jul 19, 2024

Teyi Pharmaceutical Group Co.,Ltd (SZSE:002728) announces an Equity Buyback for CNY 120 million worth of its shares.

We Think Teyi Pharmaceutical GroupLtd (SZSE:002728) Can Stay On Top Of Its Debt

Why Teyi Pharmaceutical GroupLtd's (SZSE:002728) Shaky Earnings Are Just The Beginning Of Its Problems

Investor sentiment deteriorates as stock falls 15%

First quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.33 in 1Q 2023)

Teyi Pharmaceutical Group Co.,Ltd to Report Q1, 2024 Results on Apr 20, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 22% overvalued

Teyi Pharmaceutical Group Co.,Ltd, Annual General Meeting, Mar 28, 2024

Teyi Pharmaceutical Group Co.,Ltd, Annual General Meeting, Mar 28, 2024

Teyi Pharmaceutical Group Co.,Ltd's (SZSE:002728) Shares Bounce 29% But Its Business Still Trails The Market

Here's Why We Think Teyi Pharmaceutical GroupLtd (SZSE:002728) Is Well Worth Watching

Investor sentiment deteriorates as stock falls 18%

High number of new and inexperienced directors

Teyi Pharmaceutical Group Co.,Ltd to Report Fiscal Year 2023 Results on Mar 08, 2024

Investor sentiment improves as stock rises 21%

Third quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.11 in 3Q 2022)

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.051 in 2Q 2022)

Teyi Pharmaceutical Group Co.,Ltd Announces Final Dividend on A Shares for the Year 2022, Payable on May 26, 2023

Teyi Pharmaceutical Group Co.,Ltd Approves Cash Dividend (Tax Included) for 2022

Full year 2022 earnings released: EPS: CN¥0.80 (vs CN¥0.62 in FY 2021)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 24%

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.14 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.071 (vs CN¥0.17 in 2Q 2021)

High number of new directors

Teyi Pharmaceutical Group Co.,Ltd Announces Management Appointments

Investor sentiment improved over the past week

Teyi Pharmaceutical Group Co.,Ltd Announces Final Cash Dividend on A Shares for the Year 2021, Payable on May 10, 2022

First quarter 2022 earnings released: EPS: CN¥0.21 (vs CN¥0.20 in 1Q 2021)

Investor sentiment deteriorated over the past week

Teyi Pharmaceutical Group Co.,Ltd Approves Cash Dividend (Tax Included) for the Year 2021

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.007 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.021 in 2Q 2020)

Investor sentiment improved over the past week

Teyi Pharmaceutical Group Co.,Ltd Proposes 2020 Final Profit Distribution Plan, Payable on 03 June 2021

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.22 (vs CN¥0.85 in FY 2019)

New 90-day low: CN¥10.51

New 90-day low: CN¥12.39

Teyi Pharmaceutical Group Co.,Ltd to Report Q3, 2020 Results on Oct 27, 2020

Yueke Zhijing cancelled the acquisition of 5% stake in Teyi Pharmaceutical Group Co.,Ltd (SZSE:002728) from Xu Weigao, Xu Hengqing and Xu Lifang.

New 90-day low - CN¥13.52

Earnings released

Teyi Pharmaceutical Group Co.,Ltd to Report First Half, 2020 Results on Aug 26, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘